These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Anticoagulation-associated upper gastrointestinal haemorrhage. Bell S; Nand J; Dawes M Intern Med J; 2013 Aug; 43(8):952. PubMed ID: 23919341 [No Abstract] [Full Text] [Related]
24. Cerebral infarction accompanied by cerebral bleeding in patients receiving apixaban. Kato T; Kimura M; Inoko M BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25596291 [No Abstract] [Full Text] [Related]
25. Thrombotic events after discontinuing dabigatran: rebound or resumption? Thorne KM; Dee S; Jayathissa S BMJ; 2012 Jul; 345():e4469. PubMed ID: 22761096 [No Abstract] [Full Text] [Related]
26. Dabigatran in patients with nonvalvular atrial fibrillation. Gage L J Am Coll Cardiol; 2011 Jul; 58(5):551; author reply 551. PubMed ID: 21777759 [No Abstract] [Full Text] [Related]
27. Additional events in the RE-LY trial. Connolly SJ; Wallentin L; Yusuf S N Engl J Med; 2014 Oct; 371(15):1464-5. PubMed ID: 25251519 [No Abstract] [Full Text] [Related]
28. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M; Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865 [TBL] [Abstract][Full Text] [Related]
31. NOAC and intracerebral bleeding--presentation of four cases and review of the literature. Hana A; Berthold C; Gunness VR; Hana A; Dooms G; Standhardt H; Koy J; Matgé G; Boecher-Schwarz H; Hertel F Bull Soc Sci Med Grand Duche Luxemb; 2014; (1):57-66. PubMed ID: 25011204 [TBL] [Abstract][Full Text] [Related]
32. [Dosage of the new oral anticoagulants is essential for frequency of adverse events]. Kræmmer Nielsen H Ugeskr Laeger; 2013 Feb; 175(6):331. PubMed ID: 23402233 [No Abstract] [Full Text] [Related]
33. Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Deitelzweig SB; Lin J; Kreilick C; Hussein M; Battleman D Adv Ther; 2010 Sep; 27(9):623-33. PubMed ID: 20680533 [TBL] [Abstract][Full Text] [Related]
35. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Jacobs LG Clin Geriatr Med; 2006 Feb; 22(1):17-32, vii-viii. PubMed ID: 16377465 [TBL] [Abstract][Full Text] [Related]
36. Reply to comments on "evaluation of dabigatran exposures reported to poison centers". Harrison DL; Schaeffer SE; Conway SE Ann Pharmacother; 2014 May; 48(5):664-5. PubMed ID: 24586058 [No Abstract] [Full Text] [Related]
37. Response to "evaluation of dabigatran exposures reported to poison control centers". Su M; Hoffman RS; Mercurio-Zappala M Ann Pharmacother; 2014 May; 48(5):663. PubMed ID: 24577147 [No Abstract] [Full Text] [Related]
38. [Prothrombin complex concentrate important in warfarin induced hemorrhage]. Holmström M Lakartidningen; 2009 Sep 9-15; 106(37):2270. PubMed ID: 19817159 [No Abstract] [Full Text] [Related]
39. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Lee SB; Manno EM; Layton KF; Wijdicks EF Neurology; 2006 Oct; 67(7):1272-4. PubMed ID: 17030765 [TBL] [Abstract][Full Text] [Related]
40. Predicting the risk of bleeding in patients taking warfarin. Ebell MH Am Fam Physician; 2010 Mar; 81(6):780. PubMed ID: 20229978 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]